Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Darapladib (Primary) ; Atorvastatin
- Indications Atherosclerosis; Coronary disorders
- Focus Biomarker; Therapeutic Use
- Sponsors Glaxo Research and Development Limited; GlaxoSmithKline; GSK
- 04 Jun 2019 Trial has been discontinued in UK according to European Clinical Trials Database record.
- 01 Apr 2008 Results presented at ACC in 2008
- 26 Nov 2006 New trial record.